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Analysis of the Pathomechanism and Treatment 
of Migraines Related to the Role of the 
Neuropeptide CGRP 
By: Marvi S. Qureshi
Faculty Mentor: Dr. Mohtashem Samsam
UCF Burnett School of Biomedical Sciences
ABSTRACT: Migraines are a type of headache that specifically act on only one side of the head, although about 30% 
of patients with migraines may experience a bilateral headache. Migraines are brain disorders that typically involve 
issues of sensory processing taking place in the brainstem. Possible causation has been linked to blood vessels, blood 
flow, and oxygen levels in the brain. Migraines can be described in three phases, all of which have a common 
neuropeptide known as the calcitonin gene related peptide (CGRP). CGRP increases in plasma have been linked to 
migraine headaches, and specific treatment plans have been tailored to account for this. CGRP is a vasodilator that 
causes dilation of cranial blood vessels and can lead to possible neurogenic inflammation in the periphery of its release 
while activating the pain pathway in the brainstem. The primary treatment for migraines is currently drugs from the 
triptan family and NSAIDs, as well as prophylactic drugs including antiepileptic drugs, beta-blockers, and Ca2+ 
channel blockers. This literature review will expand on this information regarding migraines, specifically discussing the 
pathophysiology, treatment, and CGRP relation to migraines through a summary of the compilation of various studies 
conducted. Through this literature review, it will then become apparent as to what research should be conducted to 
further the field of study on migraines based on what related topics have not been currently explored in depth in other 
studies.   
KEYWORDS: Migraine, Migraine Onset, CGRP, Nerve Fiber Vasodilation, Migraine Treatment Plan, Inflammation
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In general, migraines are a specific type of headache 
that involve a unilateral pulsing pain. This pain typically 
affects only one side of the head, although about 30% of 
patients may experience a bilateral headache1. Migraines 
have been found to last from four to 72 hours. Common 
symptoms associated with this pain include nausea, 
disturbed vision, vomiting, photophobia (hypersensitivity 
to light), and phonophobia (hypersensitivity to sound)1. 
Migraines are split into two different classes: the 
common and classic migraine. The majority of migraines 
are classified as common migraine. In addition, migraines 
can be described as having or lacking aura, which 
are neurological disturbances that are visual, motor, 
and sensory2. Common migraines are not typically 
accompanied with aura. The classic migraine comprises 
around 15% of total migraines and is thus the minority 
class of migraines1. 
Migraines are typically caused by issues in the cerebral 
blood vessel walls, impairment in blood flow (that 
could be due to severe vessel contraction), abnormal 
platelet numbers, varying brain oxygenation, or varying 
metabolism levels2. Migraines can be caused in response 
to a single or combined effect of all of these issues, 
and vary depending on the specific case of migraine 
displayed and on the individual displaying it. However, 
in most cases, migraines have been found to involve 
blood vessels, either intracranial or extracranial, as well 
as information communicated by the sensory nerve 
fibers to the central nervous system2. Studies conducted 
through positron emission tomography (PET) have 
indicated that the activation of the brainstem and brain 
is involved in initiating migraines and that this activation 
is constant both with and without aura3. In this literature 
review, information from a variety of studies will be 
analyzed and discussed regarding the pathophysiology, 
treatment, and CGRP effects of migraines. Afterwards, 
these experiments will be summarized to discuss future 
research that should take place to make further progress 
in this field. 
CALCITONIN GENE RELATED PEPTIDE
CGRP is an important 37 amino acid neuropeptide 
that was discovered using RNA transcripts26. These 
transcripts are from the calcitonin gene and alternative 
processing leads to different mRNAs that encode the 
hormone calcitonin27. CGRP plays an important role 
in the primary sensory neurons in which it is localized, 
specifically through the activation of the trigeminal 
system29. Its associated areas of action have a wide 
distribution from the peripheral skin, cornea, respiratory, 
and urogenital systems to the terminals close to smooth 
muscle. CGRP-containing neurons and fibers are also 
found in autonomic ganglia and in parts of the central 
nervous system and in the cerebral dura29. 
Activation of the trigeminal system as well as tissue 
stimulation and/or tissue injury causes the release of 
CGRP from the brainstem trigeminal nucleus and spinal 
cord. Cranial vasodilation, coupled with the activation 
and sensitization of sensory nerves, has been suggested 
by several studies to lead to the headache phase29. 
CGRP is a vasodilator of the cranial vessels that causes 
the nerve endings to be disturbed and the nerves to be 
pinched. This, in turn, causes more vasoactive material 
to be released, such as CGRP, producing a vicious 
cycle and resulting in neurogenic inflammation. The 
method of action has been found to be related to CGRP 
blocking the release of aldosterone secretion as well as 
promoting the release of catecholamine, which is done 
through CGRP Type 1 receptors. This action leads to the 
vasodilation effect that is associated with CGRP27. 
CGRP has also been found to enhance the activity of 
another neuropeptide, Substance P (SP), when they are 
both co–administered in the CNS. This enhanced activity 
has been suggested due to CGRP’s ability to inhibit an 
enzyme directly involved in SP degredation29. SP has 
also been linked to excitation of the neuronal network, 
where CGRP is believed to control SP degradation. 
Thus, CGRP release has been shown to have correlations 
with the duration and intensity of painful stimuli. 
CGRP receptors have been found to contain proteins 
(RAMPs, or receptor activity modifying proteins) that 
must be present to move the receptor to the membrane 
of the cell. There are various forms of RAMP: RAMP1, 
the form of RAMP that is specifically involved with 
CGRP, moves the functional glycoprotein receptor to 
the membrane surface to act as a receptor for CGRP30. 
This glycoprotein in humans is the rate-limiting factor 
for the release of CGRP in neurons31.  
Previously, CGRP receptors were separated into two 
CGRP receptor types, however, as of now, experiments 
have confirmed that there is only one CGRP receptor, 
which is the CGRP1 receptor. There are many components 
of a CGRP receptor, which include a transmembrane 
domain for a receptor activity modifying protein type 1 
9.1: 40-47
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(RAMP1), a G protein coupled receptor, and a receptor 
component protein (RCP)32. All of these components 
are necessary to form a working CGRP receptor. It has 
been determined that the first seven amino acids on the 
N-terminal end of the CGRP receptor are necessary to 
lead to the activation of the receptor, and as such various 
CGRP receptor antagonists are involved with this end of 
the protein32. 
CGRP receptors can be found in many different locations 
in many different types of cells, and are not just limited to 
the cardiovascular and nervous system. CGRP receptors 
are on glia and neurons in the central nervous system, 
as well as on many second order neurons, in addition 
to mast cells that are present inside the dura mater32. 
Various antimigraine treatments act on CGRP release 
through involvement of CGRP receptors. Nonsteroidal 
Anti–Inflammatory Drugs (NSAIDs), for example, 
block the release of CGRP that is promoted through 
the activation of the prostaglandin receptor. By contrast, 
neuronal 5HT receptors are activated by triptans, which 
lead to the blockage of CGRP release33. 
 
Dural surface electrical stimulation has led to a release 
of CGRP from trigeminal afferents. This release leads 
to vasodilation and an increase of the meningeal blood 
flow. Nitric oxide (NO) has a synergistic effect along 
with CGRP on the blood flow, and this theory has been 
proposed to explain the NO-mediated facilitation of 
CGRP synthesis and release in the trigeminal ganglia 
neurons34. CGRP promoter activity has been increased 
by overexpression of nitric oxide synthase and NO 
donors. 
Nitric oxide is a vasodilator similar to CGRP that affects 
the arterial diameter and increases it, which leads to an 
increase in blood flow throughout the brain, causing 
a similar role to CGRP in the pathomechanism of a 
migraine35. In addition, NO increases the production 
and exocytosis of CGRP, even when the stimulation 
is electrical34. Accordingly, inhibitors of nitric oxide 
synthesis prevent CGRP release37. 
Sex hormones in females are also important in the 
synthesis and the eventual expression of the receptor for 
CGRP26. 17B-estradiol leads to increased neurogenic 
vasodilation, and the mechanism through which this 
takes place is possibly through an increase of CGRP. 
This is believed to be a method by which 17B-estradiol 
exacerbates migraines in females38.
CGRP has also been found with the brain-derived 
neurotrophic factor (BDNF) in trigeminal neurons, 
making BDNF a mediator of trigeminal nociceptive 
plasticity26. BDNF is a neurotrophin that regulates 
factors such as maintenance, differentiation, and survival 
of various central and peripheral neurons.  When BDNF 
is in low concentrations, this can lead to excitation of 
neurons in the hippocampus, cerebellum, and cortex39.
CGRP has also been found to increase plasma protein 
leakage by various neuropeptides, including SP. The 
effect of these neuropeptides has been increased by 
injection of CGRP40. It has accordingly been theorized 
that the co-release of CGRP with these neuropeptides 
may have additive effects in pain. In addition, CGRP and 
SP levels have been found to increase salivary secretions 
of patients suffering from migraines26. Thus, inhibiting 
the release of these neuropeptides, specifically CGRP, is 
an important treatment for migraines.
CURRENT TREATMENT OF MIGRAINE
Prophylactic treatments are used to treat acute migraine 
attack, and are currently used as strategies to treat 
migraine headaches. Treatment methods include such 
first-line drugs as triptans and NSAIDS; in addition, 
anti-epileptic drugs, antidepressants, beta-blockers, and 
natural supplements are used to treat migraines (Table 
1)4. Acupuncture, as well as other non-drug treatments, 
is used as well. 
Medications
Drugs are utilized in the asymptomatic phase between 
acute attacks where no symptoms are observable while 
in the prophylaxis of a migraine2. These drugs include 
Timolol and Propranolol, which are both beta–blockers. 
Propranolol has been found to act by inhibiting cortical 
spreading depression in the aura phase of migraines, and 
a possible method of action to achieve this inhibition 
effect has been through the blockage of glutamate 
release41. For patients with depression or sleep issues, 
Amitriptyline, a tricyclic antidepressant, is used40. Drugs 
such as Divalproex, an anticonvulsant, and Verapamil, a 
calcium channel blocker, are also used2.
Acute attack treatment is divided into prodromal phase 
and headache phase. The prodromal phase is described 
by aura and neurological symptoms that are experienced 
prior to the actual headache26. Treatment applied during 
the prodromal phase is conducted by the Triptan family, 
9.1: 40-47
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which includes drugs such as Zolmitriptan, Naratriptan, 
Rizatriptan, Eletriptan, Almotriptan, and Sumitriptan, 
all of which have been shown to quickly decrease 
migraine headaches in patients2. Sumatriptan is the 
most widely used antimigraine drug, and is the most 
effective antimigraine prophylactic drug. This drug brings 
elevated CGRP back to normal levels and also relieves 
the headache in studies that have been conducted43. 
Triptan oral administration inhibits gastrointestinal 
mobility and thus may not completely relieve pain, and 
as such various other methods of administration such as 
nasal spray or subcutaneous injection may provide more 
effective treatment44.
Triptans have been found to be more effective when 
administered during the headache phase rather than 
during the aura phase45. In fact, the general oral 
treatment of migraine attacks (as recommended by the 
European Federation of Neurological Sciences) should 
take place earlier during the headache phase to prevent 
incorrect absorption that may take place during the 
migraine46. But if a non-oral administration of triptans 
is being given, the most effective period to administer the 
drugs has been found to be just prior to the symptoms of 
the migraine becoming severe48. A side effect of triptan 
drugs, however, is that they constrict coronary arteries, 
leading to chest tightness and pain, which can in turn 
create significant side effects in patients suffering from 
coronary diseases49. 
Another drug given during the prodromal phase is the 
vasoconstrictor Dihydroergotamine, a derivative of 
ergotamine. This drug should not be used while pregnant 
or by patients that have coronary artery disease because 
nausea is a side effect. These triptan drugs have been 
shown to be effective in most cases50.
The headache phase is associated with cerebral 
vasodilation as well as symptoms that include nausea 
or vomiting, and analgesics such as non-steroid anti-
inflammatory drugs (NSAIDs) are used for treatment26. 
These symptoms are not specific and act on many 
different receptors and molecules such as cyclooxygenase 
and other inflammation-related receptors. Naproxen, 
meclogenamate, and aspirin are common NSAIDs 
used for antimigraine treatment50. If the pain is severe, 
opioids, mepreidine, or codeine sulphate can be used to 
decrease pain. Opiates specifically decrease the calcium 
influx (pre–synaptic) and increase the potassium efflux 
(post–synaptic), which then decreases the duration of 
the action potential by decreasing the positive charge 
inside the postsynaptic terminal. Anti–emetic drugs are 
used to treat nausea, examples of which are domperidone 
and metoclopramide51. Medication overuse is lower in 
patients that are using triptan rather than analgesics, and 
opioids have been shown to have a lower efficiency at 
treating migraines overall52.
Epilepsy and migraines have similar clinical features, 
and as such antiepileptic drugs can also be used for 
antimigraine treatment due to their prevention of the 
stimulation of the brainstem4. Topiramate, gabapentin, 
and valproate are involved with gamma-aminobutyric 
acid by increasing the inhibition of GABA. Gabapentin 
and valproate alter GABA metabolism, leading to its 
eventual inhibition53. Topiramate also inhibits the 
action of GABA, but does so by acting on the receptors. 
In various double–blind trials, the actions of these 
drugs have been shown to be more positive than a 
placebo54. Topiramate has also been shown to prevent 
the exocytosis of CGRP and thus prevent vasodilation 
as well by directly acting on trigeminal sensory nerves55.
For a severe migraine attack, the first drugs of choice 
are umatriptan administered subcutaneously and 
acetylsalicylic acid administered intravenously. Steroids 
can help treat a status migrainosus. Betablockers, 
topiramate, valproic acid, and flunarizine are the first 
choice to treat the prophylaxis of migraines. Second 
choice drugs are bisoprolol, naproxen, petasites, and 
amitriptyline51. 
CONCLUSION
Considering all that has been analyzed in terms of 
migraines and the relation to CGRP in various studies that 
have been conducted, it is the author’s recommendation 
that additional CGRP receptor antagonists that are able 
to decrease the release of CGRP are the most promising 
avenue, and thus should receive particular attention. This 
experiment can effectively be conducted through analysis 
of CGRP effects under typical conditions, analysis of 
known CGRP receptor antagonists, and analysis of 
new CGRP receptor antagonists, an area where current 
research is lacking. In an ideal situation, this experiment 
would be conducted on ex-vivo dura mater from an 
animal such as a mouse.
9.1: 40-47
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Table 1. Common Medications for Anti–Migraine Treatment4
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